Value-based care can only occur if it is transformative throughout an entire healthcare system or a component of the healthcare system, said Robert Navarro, PharmD, clinical professor, College of Pharmacy, University of Florida.
Value-based care can only occur if it is transformative throughout an entire healthcare system or a component of the healthcare system, said Robert Navarro, PharmD, clinical professor, College of Pharmacy, University of Florida.
Transcript
How much progress do you think has been made in recent years in the shift to value-based care?
First of all, there are many definitions of value. If we ask the patient, the providers, healthcare plans, or the plan sponsors, we can often get a different definition of value. So, there have been many activities in the pursuit of value-based care. Often, they’ve been in very isolated components of the healthcare system, and some of them have been very effective in terms of engaging patients, increasing outcomes, and increasing drug adherence.
From a total healthcare system value-based care model, there’s been relatively slow progression. However, there’s been a lot of activity [of late], and I have great hopes for the future.
What efforts are needed to accelerate this shift?
Value-based care can only occur if this is transformative throughout an entire healthcare system or a component of the healthcare system. For example, if providers pursue a value-based care model based upon CMS reimbursement or bundled reimbursement or quality based payments, they may be very efficient in terms of improving outcomes and meeting some value outcome measurements.
However, if we forget about the patient and don’t engage the patient in many other aspects of value-based care the system may fail even though certain components may be effective. So, I think that we must be very transformative in how we approach healthcare and all of its components, in terms of engagement, making sure the incentives are properly aligned, which is very difficult to do, because when we ask patients, they have a very different perspective of what quality is. Quality, or value, to patients is access to care and affordable care.
The University of Utah study on value recently ranked 8 patient responses of “improving health outcomes.” It was more access and affordability that [patients] considered value, whereas healthcare plan leaders or pharmacy directors of pharmacy benefits may consider best outcomes and cost-effective outcomes when we consider the outcomes divided by the net cost, often used as a calculation of value.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
2 Commerce Drive
Cranbury, NJ 08512